All In Biotech

Drug Trial Radar · NCT02656329

International Study to Determine if AdreView Heart Function Scan Can be Used to Identify Patients With Mild or Moderate Heart Failure (HF) That Benefit From Implanted Medical Device

AdreView™ Myocardial Imaging for Risk Evaluation - A Multicentre Trial to Guide ICD Implantation in NYHA Class II & III Heart Failure Patients With 25%≤LVEF≤35%

Last checked: Nov 19, 2026Latest source record: May 22, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registryPivotal-lookingPhase 3. Randomized with 395 participants. This is a heuristic, not a regulatory label.

Status

Terminated

Enrollment

395

Actual

Start

Dec 30, 2015

Primary completion

May 4, 2018

Study completion May 4, 2018

Sponsor

Lead sponsor
GE HealthcareIndustry
Sponsor type
Industry
Collaborators
Advanced Clinical, LLC; TFS; H2O Clinical LLC; AG Mednet; ICON plc; ABX CRO; TransPerfect
First posted
Jan 14, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Prevention
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is an event-driven Phase IIIb, multicentre, randomised, clinical study to demonstrate the efficacy of AdreView™ imaging for appropriately guiding the decision of implantable cardioverter defibrillator (ICD) implantation, in New York Health Association (NYHA) class II and III heart failure participants with 25%\<=left ventricular ejection fraction (LVEF)\<=35%, and in particular, for identifying participants who are at low risk for sudden cardiac death and who would not benefit, or may suffer harm, from implantation of an ICD device.

Conditions

  • Heart Failure

Interventions

  • Iobenguane I -123 InjectionDrug

    Iobenguane I-123 Injection, AdreView. All participants scheduled for an Iobenguane I-123 Injection, AdreView scan.

  • Implantable Cardioverter DefibrillatorDevice

    In the Iobenguane I-123 Injection group, participants with H/M ratio less or equal to 1.6 underwent ICD device implantation, while those with H/M ratio greater than or equal to 1.6 did not undergo ICD implantation.

  • Thyroid blockingDrug

    Participants received a thyroid blocking agent before the Iobenguane I-123 Injection, AdreView, scan unless medically not indicated, according to local practice.

  • Iobenguane I -123 InjectionDrug

    Iobenguane I-123 Injection, AdreView. All participants scheduled for an Iobenguane I-123 Injection, AdreView scan.

  • Implantable Cardioverter DefibrillatorDevice

    All participants allocated to the SoC (control) group underwent ICD implantation.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. All-cause MortalityTime frame: From randomization until the end of the follow-up period (median 304 days)

Locations

94 sites in 10 countries. Site status is shown where the registry gives one.

  • Vascular Biology and Hypertension Program, University of Alabama at Birmingham

    Birmingham, Alabama

  • Comprehensive Cardiovascular Medical Group

    Bakersfield, California

  • Sharp Grossmont Hospital

    La Mesa, California

  • Yale New Haven Hospital

    New Haven, Connecticut

  • VA Connecticut Healthcare System (VACHS)

    West Haven, Connecticut

  • Cardiology Physicians PA/Red Clay Research, LLC

    Newark, Delaware

  • Bethesda Health

    Boynton Beach, Florida

  • University of Florida Health Jacksonville

    Jacksonville, Florida

  • University of Miami Hospital

    Miami, Florida

  • Cardiology Consultants

    Pensacola, Florida

  • South Miami Heart Specialists

    South Miami, Florida

  • Tampa General Hospital

    Tampa, Florida

  • University of South Florida

    Tampa, Florida

  • Augusta University

    Augusta, Georgia

  • Rush University Medical Center

    Chicago, Illinois

  • Northwestern University

    Evanston, Illinois

  • MMP ME Health Cardiology

    Scarborough, Maine

  • MedStar Shah Medical Group

    Charlotte Hall, Maryland

  • Boston Medical Center

    Boston, Massachusetts

  • Department of Cardiology, K-14 (Henry Ford Health System)

    Detroit, Michigan

  • Regions Hospital and Regions Heart Center Clinic

    Saint Paul, Minnesota

  • University at Buffalo

    Buffalo, New York

  • Advanced Cardiology Group

    Buffalo, New York

  • Montefiore Medical Center

    The Bronx, New York

  • WakeMed

    Raleigh, North Carolina

  • Veterans Affairs North Texas Healthcare System

    Dallas, Texas

  • Houston Methodist Hospital

    Houston, Texas

  • Texas Institute of Cardiology, PA

    McKinney, Texas

  • Victoria Heart and Vascular Center

    Victoria, Texas

  • Institut Universitaire De Cardiologie Et De Pneumologie De Quebec

    Québec, Canada

  • University of Calgary

    Calgary, Alberta, Canada

  • Royal Alexandra Hospital

    Edmonton, Alberta, Canada

  • London Health Sciences Centre

    London, Ontario, Canada

  • St. Michael's Hospital

    Toronto, Ontario, Canada

  • Montreal Heart Institute

    Montreal, Quebec, Canada

  • CIUSSS de L'Estrie - CHUS Hopital Fleurimont

    Sherbrooke, Quebec, Canada

  • Fakultni nemocnice Brno Bohunice

    Brno, Czechia

  • Fakultni nemocnice u sv. Anny v Brne

    Brno, Czechia

  • FN Hradec Kralove

    Hradec Králové, Czechia

  • Krajska nemocnice Liberec

    Liberec, Czechia

Showing 40 of 94 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.